GRI Bio, Inc. (GRI)

NASDAQ: GRI · IEX Real-Time Price · USD
0.760
-0.016 (-2.06%)
At close: Mar 28, 2024, 4:00 PM
0.771
+0.011 (1.43%)
After-hours: Mar 28, 2024, 6:47 PM EDT

Company Description

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States.

Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.

The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder.

GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

GRI Bio, Inc.
Country United States
Founded 2018
Industry Biotechnology
Sector Healthcare
Employees 1
CEO Dr. W. Marc Hertz Ph.D.

Contact Details

Address:
2223 Avenida De La Playa, Suite 208
La Jolla, California 92037
United States
Phone (619) 400-1171
Website gribio.com

Stock Details

Ticker Symbol GRI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001824293
ISIN Number US3622AW2059
Employer ID 82-4369909
SIC Code 2834

Key Executives

Name Position
Dr. W. Marc Hertz Ph.D. Co-Founder, Chief Executive Officer, President and Director
Leanne M. Kelly Chief Financial Officer and Corporate Secretary
Dr. Vipin Kumar Chaturvedi Ph.D. Co-Founder and Chief Scientific Officer
Dr. Albert Agro Ph.d. Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 28, 2024 424B3 Prospectus
Mar 28, 2024 424B3 Prospectus
Mar 28, 2024 10-K Annual Report
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 2, 2024 424B3 Prospectus
Feb 2, 2024 8-K Current Report
Feb 2, 2024 424B4 Prospectus
Feb 1, 2024 EFFECT Notice of Effectiveness
Jan 31, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Jan 31, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933